Afinitor's Pancreatic Tumor Indication Limited To Progressive Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of Novartis' everolimus for progressive pancreatic neuroendocrine tumors is in line with the Oncologic Drugs Advisory Committee's recommendations that the drug be reserved for those patients with more serious disease.
You may also be interested in...
Novartis Aims For 14 New Blockbuster Drugs By End Of 2017
At an investor day presentation Nov. 8, Novartis discussed a pipeline expected to yield 18 regulatory decisions over the next 24 months. The Swiss pharma currently has 139 ongoing pipeline projects, including 73 NMEs.
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.